ImmuCell Corp. (ICCC)
9.79
-0.05
(-0.51%)
USD |
NASDAQ |
Sep 09, 10:53
ImmuCell Profit Margin (Quarterly) : 25.53% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.53% |
| March 31, 2026 | 18.75% |
| December 31, 2025 | -37.36% |
| September 30, 2025 | -2.54% |
| June 30, 2025 | 7.79% |
| March 31, 2025 | 17.94% |
| December 31, 2024 | 6.64% |
| September 30, 2024 | -11.67% |
| June 30, 2024 | -27.99% |
| March 31, 2024 | -6.03% |
| December 31, 2023 | -22.37% |
| September 30, 2023 | -17.42% |
| June 30, 2023 | -39.06% |
| March 31, 2023 | -67.17% |
| December 31, 2022 | -42.65% |
| September 30, 2022 | -13.66% |
| June 30, 2022 | -17.72% |
| March 31, 2022 | 8.56% |
| December 31, 2021 | 1.36% |
| September 30, 2021 | 2.87% |
| June 30, 2021 | 3.11% |
| March 31, 2021 | -10.74% |
| December 31, 2020 | 5.05% |
| September 30, 2020 | -8.67% |
| June 30, 2020 | -25.82% |
| Date | Value |
|---|---|
| March 31, 2020 | -2.49% |
| December 31, 2019 | -8.54% |
| September 30, 2019 | -16.92% |
| June 30, 2019 | -23.14% |
| March 31, 2019 | 3.28% |
| December 31, 2018 | -35.82% |
| September 30, 2018 | -11.61% |
| June 30, 2018 | -26.49% |
| March 31, 2018 | -7.67% |
| December 31, 2017 | -6.22% |
| September 30, 2017 | -16.92% |
| June 30, 2017 | -12.48% |
| March 31, 2017 | 16.48% |
| December 31, 2016 | 1.36% |
| September 30, 2016 | 1.77% |
| June 30, 2016 | -0.39% |
| March 31, 2016 | 15.15% |
| December 31, 2015 | 10.73% |
| September 30, 2015 | 14.21% |
| June 30, 2015 | 4.80% |
| March 31, 2015 | 15.45% |
| December 31, 2014 | 5.94% |
| September 30, 2014 | 0.58% |
| June 30, 2014 | -19.15% |
| March 31, 2014 | -0.64% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 2.85% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 2.67% |
| Return on Assets | 1.74% |
| Return on Invested Capital | 1.84% |
| Gross Profit Margin (Quarterly) | 33.92% |
| Operating Margin (Quarterly) | -0.91% |
| Return on Net Operating Assets | 2.01% |